Mumbai, india: Cipla and Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) have signed an exclusive licensing and supply agreement for Rolditamig Deuderuxtecan, also known as TQB2102, a HER2 bispecific antibody-drug conjugate being evaluated for several cancers.
Under the agreement announced on August 31, 2026, Cipla will receive exclusive rights to develop and commercialise TQB2102 in India, South Africa and five other emerging markets. Cipla will handle local clinical development, regulatory activities and commercialisation in these territories, while CTTQ will continue to manufacture and supply the drug.
TQB2102 is currently being evaluated in cancers expressing HER2, including HER2-low and HER2-positive breast cancer, colorectal cancer and biliary tract cancer across multiple treatment settings. The companies said the drug has demonstrated encouraging clinical potential in patients with HER2-low advanced breast cancer.
The drug is described as a next-generation HER2 dual-epitope bispecific ADC developed independently by SBP Group. It is designed to simultaneously bind the ECD II and ECD IV domains of HER2 and uses a cleavable linker with a topoisomerase I inhibitor payload.
The dual-targeting approach is intended to distinguish TQB2102 from conventional HER2 monoclonal antibodies and single-target ADCs. According to the announcement, simultaneous binding may improve receptor cross-linking and endocytosis efficiency, potentially offering differentiated activity in cancers with lower HER2 expression.
TQB2102 has received three Breakthrough Therapy Designations from the Center for Drug Evaluation of China’s National Medical Products Administration. Its ongoing development covers multiple tumour types and treatment settings.
For Cipla, the agreement expands its oncology portfolio and gives the company development and commercial rights to a late-stage oncology asset across several emerging markets. The company will use its regulatory, medical, market-access and commercial capabilities in the licensed territories.
SBP Group will retain responsibility for manufacturing and supplying the therapy, while Cipla will lead activities required to develop and commercialise it locally.
The collaboration is intended to accelerate local development and regulatory processes and, subject to applicable approvals, support future patient access to TQB2102 across the licensed markets.
The agreement adds another potential targeted therapy to Cipla’s oncology portfolio while giving SBP Group a route to expand the international reach of its drug development pipeline.
Source: This article is based on an official press release issued by Cipla
Cipla and SBP Group sign exclusive licensing agreement for potential best-in-class HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102) | Cipla
